SOURCE: BioCentury Publications

April 08, 2010 05:00 ET

Thomson Reuters and BioCentury Convene Future Leaders in the Biotech Industry

42 Companies Offer Differentiated Products, Upcoming Milestones and Partner-Ready Assets During Biotech Bull Run

NEW YORK, NY--(Marketwire - April 8, 2010) -  BioCentury and Thomson Reuters today convened the17th Annual Future Leaders in the Biotech Industry conference in New York City with a program to showcase fresh opportunities during the current bull market for biotech stocks. The event features 42 biopharma companies independently selected for their upcoming news flow, ability to attract capital, unpartnered compounds and their potential to deliver upside for investors and pharma deal makers.

In fact, the public companies at Future Leaders are among the pace setters in the current biotech stock market rally. They collectively are up 100% over the past year, easily out-distancing the 37% jump in the BioCentury 100 Index and the 38% gain in the NASDAQ Biotechnology Index (NBI). Over that same period, the aggregate market cap of the Future Leaders public companies has more than doubled, from $3.4 billion to $7.0 billion.

The Future Leaders Class of 2010 includes 24 public and 18 private companies that have raised $5.8 billion in capital, including $1.6 billion since the beginning of 2009.

These Future Leaders have 21 marketed products, including 11 therapeutics and 10 diagnostics, 15 programs in Phase III, 72 programs in Phase II and 79 programs in Phase I development. The companies have at least 98 programs in preclinical development, including 85 that are currently unpartnered.

The disease space covers cancer, infectious diseases, neurology, gastrointestinal, cardiovascular and metabolic disorders.

"There's still money on the sidelines and investors expect plenty of news flow in the second quarter to push biotech stocks higher," said David Flores, BioCentury's President & CEO. "BioCentury's 2Q Financial Markets Preview this week notes that that mid- and large cap leaders will continue to create product news, while more M&A and more high-profile tier-jumpers should drive an influx of money from generalist investors who haven't yet participated in the rally."

More than 750 investment professionals and pharmaceutical business development and licensing executives have pre-registered for today's event at the Millennium Broadway Hotel and Conference Center. Money managers attending control $1.2 trillion in equity assets, $140 billion in healthcare assets, and $33 billion in biotech assets.

The 2010 Presenting Companies

Today's presenting companies were screened using Thomson Reuters and BioCentury industry analysis and proprietary databases, including BioCentury's BCIQ online business intelligence platform. The result is an independently selected mix of companies with proven fundraising capacity, the prospect for key partnerships and proximity to potentially transformational milestones. (Stock symbols shown for publicly traded companies; listed on NASDAQ unless noted).

Akebia Therapeutics Inc.
Allos Therapeutics Inc. (ALTH)
Amarin Corp. plc (AMRN)
ArQule Inc. (ARQL)
Biota Holdings Ltd. (ASX:BTA)
Calistoga Pharmaceuticals Inc.
Chelsea Therapeutics International Ltd. (CHTP)
ChemoCentryx Inc.
Chimerix Inc.
Clinical Data Inc. (CLDA)
Curis Inc. (CRIS)
Cytori Therapeutics Inc. (CYTX: XMPA); XETRA: XMPA)
Depomed Inc. (DEPO)
Dyax Corp. (DYAX)
Enobia Pharma Inc.
Exact Sciences Corp.
Five Prime Therapeutics Inc.
Gemin X Pharmaceuticals Inc.

GlobeImmune Inc.
Inovio Biomedical Corp. (NYSE Amex:INO)
iPierian Inc.
KAI Pharmaceuticals Inc.
KaloBios Pharmaceuticals Inc.
Lux Biosciences Inc.
Micromet Inc. (MITI)
Neoprobe Corp. (OTCBB:NEOP)
NeurogesX Inc. (NGSX)
Newron Pharmaceuticals S.p.A. (SIX: NWRN)
PDL BioPharma Inc. (PDLI)
Pharming Group N.V. (Euronext: PHARM)
Plexxikon Inc.
Protalix Biotherapeutics Inc. (PLX)
PTC Therapeutics Inc.
Regulus Therapeutics Inc.
Relypsa Inc.
RXi Pharmaceuticals Corp.
Seaside Therapeutics LLC
Singulex Inc.
SuperGen Inc. (SUPG)
Trubion Inc. (TRBN)
Vivus Inc. (VVUS)
Wilex AG (XETRA:WL6)

For the Presenting Company schedule and additional program highlights, CLICK HERE.

Top Sponsors Demonstrate Long-Term Commitment to Industry

Anchored by Gold Sponsor Cooley Godward Kronish LLP, the prestigious group of 2010 sponsors includes leaders from both the public and private capital markets: OrbiMed Advisors, Rodman & Renshaw, WBB Securities, Wedbush Pacific Growth Life Sciences and Yorkville Advisors.

This premier Wall Street event is one of two annual investor conferences organized by BioCentury and Thomson Reuters. The next conference, NewsMakers in the Biotech Industry, will take place in New York City on September 15, 2010.

About BioCentury
BioCentury Publications, Inc. provides essential biopharma industry intelligence from five offices in the U.S. and Europe. For more than 17 years, a global audience of biotech and pharmaceutical executives and investors has benefited from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications, data products and collaborative industry conferences in the U.S., Europe and Asia. BioCentury's titles include the flagship BioCentury, the Bernstein Report on BioBusiness; its SciBX: Science-Business eXchange translational science joint publishing venture with Nature Publishing Group; and its BioCentury Extra online daily newspaper. These timely journals are backed by BCIQ: BioCentury Online Intelligence, an online business intelligence resource. For more information, visit

About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people and operates in over 100 countries. For more information, go to

BioCentury®; The Bernstein Report on BioBusiness™ and BCIQ are trademarks of BioCentury Publications, Inc. SciBX and SciBX: Science-Business eXchange are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.

Contact Information